India's Traditional Knowledge Digital Library (TKDL), which has a database containing formatted…

Question

India's Traditional Knowledge Digital Library (TKDL), which has a database containing formatted information on more than 2 million medicinal formulations is proving a powerful weapon in the country's fight against erroneous patents. Discuss the pros and cons of making this database publicly available under open-source licensing.

Ghissu Editorial · Accepted Answer

Open-source release of TKDL would give examiners worldwide prior art and boost research, but would ease biopiracy by derivation and surrender benefit-sharing leverage, so tiered access is wiser. India built TKDL in 2001 after costly battles to revoke the turmeric and neem patents.

**Introduction**

After costly battles to revoke the turmeric (1997) and neem (2000) patents, CSIR and the AYUSH ministry built the Traditional Knowledge Digital Library (TKDL) in 2001. For most of its life only patent offices under non-disclosure agreements could search it, so opening it under an open-source licence cuts both ways.

**Pros of Releasing TKDL Under Open-Source Licensing**

1. **Universal prior art**: All examiners and opponents worldwide, not only the EPO and USPTO, could cite it, blocking wrong patents before grant.
2. **Research and innovation**: AYUSH researchers and start-ups could mine formulations for drug leads, as Tu Youyou's reading of a classical Chinese text yielded artemisinin (Nobel 2015).
3. **Validation and commons**: Open data invites clinical scrutiny and keeps community knowledge in a public domain that no single firm can enclose.

**Cons and Risks of an Open Release**

SKETCH: spectrum | TKDL Access Choices
left: Closed
right: Fully open
- Patent offices only
- Tiered paid access
- Open with benefit sharing
- Open-source commons

1. **Biopiracy by derivation**: A translated, searchable database is a ready lead list for firms abroad to patent derivatives such as isolated molecules, which an open licence cannot stop.
2. **Lost benefit sharing**: The Biological Diversity Act, 2002 and the Nagoya Protocol rest on prior informed consent and benefit sharing; free release surrenders that leverage.
3. **Enforcement and consent**: Licence terms are hard to enforce abroad, the knowledge holders were never consulted, and unvalidated remedies risk unsafe self-medication.

**Conclusion**

Full open-source release would weaken a proven shield. Tiered access, open to examiners and Indian researchers but licensed with benefit sharing for commercial users, keeps TKDL a weapon against erroneous patents while serving innovation and the communities who own this knowledge.

Model answer

Practise this question

Intellectual Property Rights5 questions

Ghissu